Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
  • CME/MOC
    • Articles
    • Calendar
  • COVID-19
    • Curbside Consults Overview
    • Pulmonary/ICU
    • Patient Subsets & Specific Organ Involvement
    • Therapies
    • Imaging & Procedures
    • Patients with Underlying Disease
    • Virus Background & Testing
    • Healthcare System Practice
  • Info For
    • Manuscript Submission
      • 1-Minute Consult
      • Commentary
      • Current Drug Therapy
      • Editorial
      • Guidelines to Practice
      • Interpreting Key Trials
      • Letter to the Editor
      • Review
      • Smart Testing
      • Symptoms to Diagnosis
      • The Clinical Picture
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
  • Conference Coverage
    • ASH Annual Meeting
    • AHA Sessions 2020
    • IDWeek 2020
    • CHEST 2020
    • ADA 2020
    • ACC 2020
  • Advertise
    • Media Kit
    • Contact
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
  • CME/MOC
    • Articles
    • Calendar
  • COVID-19
    • Curbside Consults Overview
    • Pulmonary/ICU
    • Patient Subsets & Specific Organ Involvement
    • Therapies
    • Imaging & Procedures
    • Patients with Underlying Disease
    • Virus Background & Testing
    • Healthcare System Practice
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
  • Conference Coverage
    • ASH Annual Meeting
    • AHA Sessions 2020
    • IDWeek 2020
    • CHEST 2020
    • ADA 2020
    • ACC 2020
  • Advertise
    • Media Kit
    • Contact
Review

Oral immunotherapy: The answer to peanut allergy?

Rachel M. Whitsel, APRN, Jaclyn A. Bjelac, MD, Ahila Subramanian, MD, Alice E. W. Hoyt, MD and Sandra J. Hong, MD
Cleveland Clinic Journal of Medicine February 2021, 88 (2) 104-109; DOI: https://doi.org/10.3949/ccjm.88a.20130
Rachel M. Whitsel
Department of Allergy and Clinical Immunology, Food Allergy Center of Excellence., Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaclyn A. Bjelac
Department of Pediatric Allergy and Clinical Immunology, Food Allergy Center of Excellence, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
Ahila Subramanian
Department of Allergy and Clinical Immunology, Food Allergy Center of Excellence, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
Alice E. W. Hoyt
Department of Allergy and Clinical Immunology, Food Allergy Center of Excellence, Cleveland Clinic; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
Sandra J. Hong
Department of Allergy and Clinical Immunology, Food Allergy Center of Excellence, Cleveland Clinic; Clinical Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hongs3@ccf.org
  • Find this author on Cleveland Clinic
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Peanut and tree-nut allergies have increased dramatically in prevalence, especially in children. Historically, children with food allergies have been treated through strict avoidance of the allergen. Recently, an oral preparation of peanut allergen (Palforzia) was approved for immunotherapy (ie, desensitization) in children 4 to 17 years old. This article reviews oral immunotherapy and its role in children with peanut allergies.

  • Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.
View Full Text

REFERENCES

  1. ↵
    1. Gupta RS,
    2. Warren CM,
    3. Smith BM, et al
    . The public health impact of parent-reported childhood food allergies in the United States. Pediatrics 2018; 142(6):e20181235. doi:10.1542/peds.2018-1235
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Food Allergy Research & Education (FARE)
    . Facts and statistics: key information to help better understand food allergies and anaphylaxis. Accessed January 21, 2021. https://www.foodallergy.org/resources/facts-and-statistics.
  3. ↵
    1. Fierstein JL,
    2. Brown D,
    3. Gupta R,
    4. Bilaver L
    . Understanding food-related allergic reactions through a US national patient registry. J Allergy Clin Immunol Pract 2020; S2213–S2198(20)30827–8. doi:10.1016/j.jaip.2020.08.011
    OpenUrlCrossRef
  4. ↵
    1. Sicherer SH,
    2. Muñoz-Furlong A,
    3. Godbold JH,
    4. Sampson HA
    . US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol 2010; 125(6):1322–1326. doi:10.1016/j.jaci.2010.03.029
    OpenUrlCrossRefPubMed
  5. ↵
    1. Hourihane JO,
    2. Dean TP,
    3. Warner JO
    . Peanut allergy in relation to heredity, maternal diet, and other atopic diseases: results of a questionnaire survey, skin prick testing, and food challenges. BMJ 1996; 313(7056):518–521. doi:10.1136/bmj.313.7056.518
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Lack G
    . Update on risk factors for food allergy. J Allergy Clin Immunol 2012; 129(5):1187–1197. doi:10.1016/j.jaci.2012.02.036
    OpenUrlCrossRefPubMed
  7. ↵
    1. Gupta RS,
    2. Walkner MM,
    3. Greenhawt M, et al
    . Food allergy sensitization and presentation in siblings of food allergic children. J Allergy Clin Immunol Pract 2016; 4:(5)956–962. doi:10.1016/j.jaip.2016.04.009
    OpenUrlCrossRef
  8. ↵
    1. Du Toit G,
    2. Roberts G,
    3. Sayre PH, et al
    . Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 2015; 372(9):803–813. doi:10.1056/NEJMoa1414850
    OpenUrlCrossRefPubMed
  9. ↵
    1. Hourihane JO,
    2. Roberts SA,
    3. Warner JO
    . Resolution of peanut allergy: case-control study. BMJ 1998; 316(7140):1271–1275. doi:10.1136/bmj.316.7140.1271
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Wasserman RL,
    2. Jones DH,
    3. Windom HH
    . Oral immunotherapy for food allergy: the FAST perspective. Ann Allergy Asthma Immunol 2018; 121(3):272–275. doi:10.1016/j.anai.2018.06.011
    OpenUrlCrossRef
  11. ↵
    1. Chu DK,
    2. Wood RA,
    3. French S, et al
    . Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet 2019; 393(10187):2222–2232. doi:10.1016/S0140-6736(19)30420-9
    OpenUrlCrossRefPubMed
  12. ↵
    1. Yu W,
    2. Freeland DMH,
    3. Nadeau KC
    . Food allergy: immune mechanisms, diagnosis and immunotherapy. Nat Rev Immunol 2016; 16(12):751–765. doi:10.1038/nri.2016.111
    OpenUrlCrossRef
  13. ↵
    1. Feuille E,
    2. Nowak-Węgrzyn A
    . Oral immunotherapy for food allergies. Ann Nutr Metab 2016; 68(suppl 1):19–31. doi:10.1159/000445391
    OpenUrlCrossRef
    1. Freeland DMH,
    2. Manohar M,
    3. Andorf S,
    4. Hobson BD,
    5. Zhang W,
    6. Nadeau KC
    . Oral immunotherapy for food allergy. Semin Immunol 2017; 30:36–44. doi:10.1016/j.smim.2017.08.008
    OpenUrlCrossRef
  14. ↵
    1. Palforzia
    . Prescribing information. Aimmune Therapeutics; 2020. Accessed January 21, 2021. https://www.fda.gov/media/134838/download.
  15. ↵
    1. PALISADE Group of Clinical Investigators,
    2. Vickery BP,
    3. Vereda A,
    4. Casale TB, et al
    . AR101 oral immunotherapy for peanut allergy. N Engl J Med 2018; 379(21):1991–2001. doi:10.1056/NEJMoa1812856
    OpenUrlCrossRefPubMed
  16. ↵
    1. Aimmune Therapeutics
    . Press release: new two-year Palforzia™ data show on-going safety and efficacy and continued immunomodulation in patients with peanut allergy. June 8, 2020. Accessed January 21, 2021. https://ir.aimmune.com/news-releases/news-release-details/new-two-year-palforziatm-data-show-going-safety-and-efficacy-and.
  17. ↵
    1. US Food and Drug Administration
    . Approved risk evaluation and mitigation strategies (REMS): Palforzia (peanut (Arachis hypogaea) allergen powder-dnfp). Accessed January 21, 2021. https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=398.
  18. ↵
    1. Shaker M,
    2. Greenhawt M
    . Estimation of health and economic benefits of commercial peanut immunotherapy products: a cost-effectiveness analysis. JAMA Netw Open 2019; 2(5):e193242. doi:10.1001/jamanetworkopen.2019.3242
    OpenUrlCrossRef
  19. ↵
    1. Epstein-Rigbi N,
    2. Goldberg MR,
    3. Levy MB,
    4. Nachshon L,
    5. Elizur A
    . Quality of life of food-allergic patients before, during, and after oral immunotherapy. J Allergy Clin Immunol Pract 2019; 7(2):429–436.e2. doi:10.1016/j.jaip.2018.06.016
    OpenUrlCrossRef

This article requires you to have a ccjm.org account to view the full text. If you already have an account, you may log in below to view this article along with all other CCJM content. If you do not have an account, register here. It’s free!

Log in using your username and password

Forgot your user name or password?
PreviousNext
Back to top

Registration is Now Required for Free Access to CCJM Content

Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.

If you are using a mobile device, click on the settings icon to access the Register link.

In this issue

Cleveland Clinic Journal of Medicine: 88 (2)
Cleveland Clinic Journal of Medicine
Vol. 88, Issue 2
1 Feb 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Oral immunotherapy: The answer to peanut allergy?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Oral immunotherapy: The answer to peanut allergy?
Rachel M. Whitsel, Jaclyn A. Bjelac, Ahila Subramanian, Alice E. W. Hoyt, Sandra J. Hong
Cleveland Clinic Journal of Medicine Feb 2021, 88 (2) 104-109; DOI: 10.3949/ccjm.88a.20130

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Oral immunotherapy: The answer to peanut allergy?
Rachel M. Whitsel, Jaclyn A. Bjelac, Ahila Subramanian, Alice E. W. Hoyt, Sandra J. Hong
Cleveland Clinic Journal of Medicine Feb 2021, 88 (2) 104-109; DOI: 10.3949/ccjm.88a.20130
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • A NEW TREATMENT OPTION
    • GRADUALLY INCREASING DOSES
    • WHAT ARE THE EFFICACY AND SAFETY CONCERNS OF ORAL IMMUNOTHERAPY?
    • IMPLEMENTING A PROGRAM: COST, TRAINING, RISKS, LIMITATIONS
    • AN EXCITING TIME OF EMERGING OPTIONS
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Cardiac surveillance for anti-HER2 chemotherapy
  • Precision treatment for metastatic non–small cell lung cancer: A conceptual overview
Show more Review

Similar Articles

Subjects

  • Drug Therapy
  • Allergy/Immunology
  • Adolescent Medicine

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit
  • Advertise Contact

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • Advertisers
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2021 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire